Cargando…

Factors associated with development and persistence of post-COVID conditions: A cross-sectional study()

INTRODUCTION: The post-COVID condition has become a social concern. Although the patient characteristics associated with the development of this condition are partially known, those associated with its persistence have not been identified. METHODS: We conducted a cross-sectional questionnaire-based...

Descripción completa

Detalles Bibliográficos
Autores principales: Miyazato, Yusuke, Tsuzuki, Shinya, Morioka, Shinichiro, Terada, Mari, Kutsuna, Satoshi, Saito, Sho, Shimanishi, Yumiko, Takahashi, Kozue, Sanada, Mio, Akashi, Masako, Kuge, Chika, Osanai, Yasuyo, Tanaka, Keiko, Suzuki, Michiyo, Hayakawa, Kayoko, Ohmagari, Norio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9114006/
https://www.ncbi.nlm.nih.gov/pubmed/35595598
http://dx.doi.org/10.1016/j.jiac.2022.04.025
Descripción
Sumario:INTRODUCTION: The post-COVID condition has become a social concern. Although the patient characteristics associated with the development of this condition are partially known, those associated with its persistence have not been identified. METHODS: We conducted a cross-sectional questionnaire-based survey among patients who had recovered from COVID-19 and visited the National Center for Global Health and Medicine between February 2021 and March 2021. Demographic and clinical data, and data regarding the presence and duration of post-COVID conditions were obtained. We identified factors associated with the development and persistence of post-COVID conditions using multivariate logistic and linear regression analyses, respectively. RESULTS: We analyzed 457 of 526 responses (response rate, 86.9%). The median patient age was 47 years. Of these, 378 patients (84.4%) had mild disease in the acute phase. The number of patients with symptoms at 6 and 12 months after onset or diagnosis was 120 (26.3%) and 40 (8.8%), respectively. Women were at risk of developing fatigue (odds ratio [OR]: 2.03, 95% confidence interval [CI]: 1.31–3.14), dysosmia (OR: 1.91, 95%CI: 1.24–2.93), dysgeusia (OR: 1.56, 95%CI: 1.02–2.39), hair loss (OR: 3.00, 95%CI: 1.77–5.09), and persistence of any symptoms (coefficient: 38.0, 95%CI: 13.3–62.8). Younger age and low body mass index were factors for developing dysosmia (OR: 0.96, 95%CI: 0.94–0.98 and OR: 0.94, 95%CI: 0.89–0.99, respectively) and dysgeusia (OR: 0.98, 95%CI: 0.96–1.00 and OR: 0.93, 95%CI: 0.88–0.98, respectively). CONCLUSION: We identified factors involved in the development and persistence of post-COVID conditions. Many patients, even those with mild conditions, experience long-term residual symptoms.